SAN JOSE, Calif.—Using $11 million in new venture capital funding, Predicant Biosciences acquired Pathwork Informatics, naming the newly merged company Pathwork Diagnostics, developing and commercializing innovative genomic diagnostic tests for oncology. The first product developed by Pathwork Diagnostics will be a test for the origin of secondary and/or unspecified malignancies.
"We believe Pathwork Diagnostics' innovative cancer tests will bring the routine application of personalized medicine one step closer to reality," says Deborah J. Neff, Predicant CEO, who was named president and CEO of the new company. "The microarray-based diagnostic tests under development will provide clinicians with previously unavailable diagnostic insights that will transform cancer patient care and ultimately help improve outcomes."
